Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Li… Read more
Pharmosa Biopharm Inc. (6875) - Total Liabilities
Latest total liabilities as of June 2024: NT$225.10 Million TWD
Based on the latest financial reports, Pharmosa Biopharm Inc. (6875) has total liabilities worth NT$225.10 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmosa Biopharm Inc. - Total Liabilities Trend (2020–2023)
This chart illustrates how Pharmosa Biopharm Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmosa Biopharm Inc. Competitors by Total Liabilities
The table below lists competitors of Pharmosa Biopharm Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gamehost Inc
PINK:GHIFF
|
USA | $60.50 Million |
|
Circus SE
XETRA:CA1
|
Germany | €16.62 Million |
|
CH Biotech R&D Co., Ltd.
TW:6534
|
Taiwan | NT$1.06 Billion |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
Turkey | TL1.89 Billion |
|
Asia Plus Group Holdings PCL
BK:ASP
|
Thailand | ฿4.53 Billion |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
Germany | €210.36 Million |
|
Nextensa NV
BR:NEXTA
|
Belgium | €815.25 Million |
|
Fiera Milano SpA
F:FM3
|
Germany | €595.29 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Pharmosa Biopharm Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmosa Biopharm Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmosa Biopharm Inc. (2020–2023)
The table below shows the annual total liabilities of Pharmosa Biopharm Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$195.99 Million | +412.42% |
| 2022-12-31 | NT$38.25 Million | -30.37% |
| 2021-12-31 | NT$54.93 Million | -60.03% |
| 2020-12-31 | NT$137.44 Million | -- |